Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401167 | 0.84 | KLK7 (0.61) | KLK7TLR2TLR1KMT2AMEN1 | |
| SCHEMBL3912355 | 0.84 | KLK7 (0.61) | KLK7TLR2TLR1KMT2AMEN1 | |
| SCHEMBL29398857 | 0.79 | KLK7 (0.53) | KLK7TLR2TLR1KMT2AMEN1 | |
| SCHEMBL9354561 | 0.79 | KLK7 (0.56) | KLK7TLR2TLR1KMT2AP2RX7 | |
| SCHEMBL9354881 | 0.78 | KLK7 (0.60) | KLK7TLR2TLR1P2RX7 | |
| SCHEMBL7441367 | 0.77 | KLK7 (0.53) | KLK7TLR2TLR1KMT2AMEN1 | |
| SCHEMBL9354935 | 0.76 | KLK7 (0.57) | KLK7TLR2TLR1P2RX7 | |
| SCHEMBL5709602 | 0.75 | KLK7 (0.51) | KLK7TLR2TLR1KMT2AMEN1 | |
| SCHEMBL9025557 | 0.74 | KLK7 (0.58) | KLK7TLR2TLR1 | |
| SCHEMBL5891788 | 0.73 | KMT2A (0.45) | KMT2AMEN1MAPK1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |